Oil prices fall below 100 yuan+Besent calls out, U.S. Treasury yields retreat from 2002 highs
U.S. Treasury yields have retreated from their highest levels since 2002.
According to Zhihui Finance APP, U.S. Treasury yields have retreated from their highest levels since 2002, as oil prices fell below $100 per barrel and U.S. Treasury Secretary Scott Besant insisted that the government debt burden is manageable. The yields on 10-year and 30-year U.S. Treasury bonds dropped by 3 and 4 basis points, to 5.27% and 5.63% respectively, while the 2-year yield remained largely unchanged. On Tuesday, oil prices declined as signs emerged that more crude oil is being supplied through the Strait of Hormuz.
This signals a pause in the global bond market sell-off, which previously continued due to concerns over inflation triggered by conflict between the U.S. and Iran, and a rising expectation of further monetary tightening by the Federal Reserve.
Besant attempted to reassure investors, stating that a combination of economic growth and spending restrictions will “soon” begin to change the U.S. government’s borrowing trajectory. In a fireside chat in Pennsylvania on Monday evening, he said the government would start “reversing this trend.”
Voices of Doubt: Deficit Unsolved, Reassurance Falls Short
Nevertheless, the market remains skeptical of Besant’s statements and is reluctant to declare that the bond market sell-off has ended.
Macquarie strategist Gareth Berry commented: “Given the deficit is as high as 6% and there are no plans to cut the deficit, the market may remain very doubtful. Speaking about targets is not the same as having a plan.”
Schroders fund manager James Ling said he is focused not only on crude prices. “To see a meaningful rebound across the entire curve, the primary condition is for energy prices to start falling,” he said. “It’s not just about crude oil prices, but also refined product prices.”
Additionally, Bridgewater founder Ray Dalio warned that the U.S. is approaching the limit of the debt cycle and, if spending continues to exceed earnings, may face a crisis within three years. He said U.S. Treasuries are vulnerable to decreased demand from China and Japan (the two largest foreign holders of U.S. debt).
However, HSBC strategists believe the market’s bet on roughly 80 basis points of Federal Reserve rate hikes by 2027 is “excessive,” but they still maintain that the yield spread between 5-year and 30-year U.S. Treasuries will widen. HSBC U.S. rates strategist Dheeraj Narula wrote in a report: “We believe that surging volatility, combined with historical data showing a lack of clear technical resistance at these levels, has led many investors to adopt a wait-and-see stance, although the appeal of higher long-term yields is increasingly evident.”
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Japanese Yen: Range trade holds against US Dollar as Fed path questioned – Rabobank
BUZZ-GEO Group shares rise after completing $650 million debt refinancing
On October 6, shares of prison operator GEO Group (GEO.N) rose 2.6% in premarket trading to $33.19. The company conducted a debt refinancing, redeeming $650 million in senior secured notes due in 2029. Its $550 million revolving credit facility maturity was extended to July 2031. Earlier this week, the company agreed to sell its ICE processing center complex in Adelanto, California for $950 million. The company also recently increased its share repurchase authorization to $1.25 billion. As of the close of the previous trading day, the company's share price had more than doubled this year. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translations and provides them for the convenience of readers only. Reuters assumes no responsibility for any damage or loss arising from the use of automated translation.)
Updated: 2-ArriVent’s oral lung cancer therapy fails in late-stage clinical trial, shares plunge
In the first paragraph, stock information was added. Paragraphs 2 to 8 provide a detailed introduction to the disease and the clinical trial situation. Reuters, Oct. 6 - ArriVent BioPharma (AVBP.O) said on Tuesday that its oral therapy for treating rare lung cancer failed to meet its primary goal of delaying disease progression in a late-stage clinical trial, leading to its shares plunging by 63% in premarket trading. The therapy, firmonertinib, targets previously untreated advanced non-small cell lung cancer (NSCLC) patients who carry a gene mutation called the EGFR exon 20 insertion, which can promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC represents about 85% of all lung cancer cases. In the trial, according to independent reviewers, the 240mg dosage developed by ArriVent extended median progression-free survival to 11 months, compared to 9.5 months in the chemotherapy group. Chief Executive Officer Bing Yao stated that the improvement in progression-free survival (defined as the length of time patients live without worsening or spread of disease) was not significant. "These disappointing results are not what we had hoped for, especially for patients with EGFR exon 20 insertion-mutant NSCLC who are in urgent need of more effective treatments," said Yao. The company is evaluating the full data set to determine the most suitable development path for firmonertinib. ArriVent stated that no new safety signals were observed in the trial. The therapy has already been approved in China for non-small cell lung cancer patients carrying specific mutations. (For the convenience of non-English language speakers, Reuters has automated the translation of its reporting into several other languages. Due to possible errors or missing context in automated translation, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters accepts no responsibility for any damages or losses caused by the use of the automated translation feature.)
Sector Update: Consumer Stocks Edge Higher Premarket Tuesday
09:15 AM EDT, 10/06/2026 (MT Newswires) -- Consumer stocks were edging higher premarket Tuesday, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) up 0.1% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) advancing by 0.4%. Nomad Foods (NOMD) stock was up nearly 3% after the company said it now expects fiscal 2026 organic revenue to decline 2% to 3%, compared with its previous guidance for a decline of 2% to 5%. PepsiCo (PEP) and Monster Beverage (MNST) can continue to label their cans in India as energy drinks after a court ruling, Reuters reported, citing a lawyer present at the hearing. PepsiCo shares were slightly higher and Monster Beverage stock was down 0.3% pre-bell. B&G Foods (BGS) said it cancelled its agreement to sell Green Giant Canada to Nortera Foods on Monday, after failing to obtain Canadian regulatory approval. Shares of B&G Foods were up more than 1% premarket.
Crypto prices
More
